Prevalence & Testing for KRAS G12C Mutation in NSCLC

Select disease state





~ 13% (1 in 8) of patients with non-squamous NSCLC have the KRAS G12C mutation, yet too many of these patients go unidentified.

Consider testing for all actionable mutations in eligible patients with NSCLC at diagnosis and help Find KRAS G12C.


KRAS, Kirsten rat sarcoma; NSCLC, non-small cell lung cancer.

Reference: Data on file, Amgen; [Analysis of AACR Genie v12].